Related Experiment Video
Updated: Sep 20, 2025
OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery
Published on: May 9, 2021
Progestin prime ovarian stimulation provides comparable outcomes to GnRH antagonist in donor cycles with vitrified
Lucía Murria1, Juan Giles1, Lorena Bori1
1IVIRMA Global Research Alliance - IVIRMA Valencia, Valencia, Spain; IVIRMA Global Research Alliance - IVI Foundation, Instituto de Investigación Sanitaria La Fe (IIS La Fe), Valencia, Spain.
Objective:
To compare the effectiveness and safety of medroxyprogesterone acetate (MPA) and gonadotropin-releasing hormone antagonist (GnRHant) protocols in vitrified donor oocyte cycles and expand the current evidence on their clinical outcomes.
Design:
Retrospective cohort study.
Subjects:
This study included 14,981 recipients who received vitrified oocytes coming from 3,599 donors stimulated with MPA and 4,998 donors stimulated with GnRHant.
Exposure:
Pituitary suppression during ovarian stimulation with either MPA or GnRHant protocols.
Main Outcome Measures:
Clinical metrics included implantation, clinical pregnancy rate, ongoing pregnancy rate and cumulative live birth rate. Nonclinical metrics included artificial intelligence (AI)-based oocyte and embryo quality scores.
Results:
The MPA group demonstrated significantly higher oocyte survival rates postwarming (90.17% vs. 88.41%) and blastocyst formation rates (57.58% vs. 53.99%) compared with the GnRHant group. Artificial intelligence-based evaluations revealed no significant differences in oocyte (5.9 ± 2.8 vs. 6.0 ± 2.9) or embryo (5.0 ± 2.6 vs. 5.1 ± 2.7) scores between the 2 groups. Clinical outcomes, including implantation rate (57.68% vs. 55.82%), clinical pregnancy rate (58.17% vs. 58.14%), ongoing pregnancy rate (49.40% vs. 48.15%) and cumulative live birth rate (65.60% vs. 65.50%), were comparable between MPA and GnRHant protocols. The paired analysis of donors stimulated with both protocols supported these findings, showing no significant differences in clinical outcomes. Finally, the Generalized Estimating Equations (GEEs) model identified significant predictors of live birth, including recipient age, recipient body mass index (BMI), number of metaphase II (MII) oocytes, embryo quality, and the number of warmed MII oocytes, whereas the type of pituitary suppression protocol (MPA vs. GnRHant) did not significantly impact live birth rates (odds ratio: 1.09 [95% confidence interval: 0.97-1.23]).
Conclusion:
Medroxyprogesterone acetate and GnRHant protocols yielded comparable clinical outcomes in vitrified donor oocyte cycles. Artificial intelligence-based assessments showed consistency with clinical outcomes, detecting no significant differences in oocyte or embryo quality between protocols. These results support the use of MPA as a cost-effective, patient-friendly alternative in donor oocyte vitrification cycles, providing robust evidence for its clinical application.
Related Concept Videos
01:24In Vitro Fertilization
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...
01:30Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
01:27Ovarian Cycle